Thus, identifying novel biomarkers for the prediction of platinum-sensitive patients should be highly significant in the chemotherapy of NSCLC patients.
← all excerpts
CRTAC1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression.
1
—
—